New combo before lung surgery shows promise in early trial
NCT ID NCT07050056
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether giving the immunotherapy drug tislelizumab along with radiation therapy before surgery can help eliminate more cancer in people with resectable non-small cell lung cancer (NSCLC). About 20 participants will receive the combination, then have surgery to remove their tumor. The main goal is to see how many patients have no cancer left in the removed tissue (complete pathological response).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab (a drug that helps the immune system fight cancer) and radiation therapy
- What this could lead to
- If successful, this combination could become a new standard approach to shrink tumors before surgery, potentially improving survival for people with early-stage lung cancer.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The combination of immunotherapy and radiation can cause serious side effects like lung inflammation or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Northern People Hospital
RECRUITINGYangzhou, Jiangsu, 225001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.